{"success":true,"data":{"pressRelease":{"id":"50806","rtpr_id":"nGNX75c4bp","ticker":"AIM","exchange":"NYSE American","all_tickers":["AIM"],"title":"AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones","author":"Globe Newswire","published_at":"2026-06-01T12:58:00.099Z","article_body":"OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.\n(https://www.globenewswire.com/Tracker?data=5rGktpu2xpylAlM1y0tFodD_VXgDBHDlHw4FDZcDFbqKa6hNgjNvdAuwkwQqG9W282fLruEWsBhNPOgubgXh1X_AFGJ1jtUnCxm5k0O2WAI=)\n(NYSE American: AIM) (“AIM” or the “Company”) today announced a\nsignificant milestone in its pancreatic cancer development program, with\nenrollment of the final subject, barring disqualifying pre-treatment\ncircumstances. The final planned subject is scheduled for treatment in\nmid-June, surpassing the Company's original enrollment target of July 2026 in\nthe Phase 2 clinical trial of AIM’s drug Ampligen(®) (rintatolimod)\ncombined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor\nImfinzi(®) (durvalumab) in the treatment of metastatic pancreatic cancer\npatients with stable disease post-FOLFIRINOX standard of care (the\n“DURIPANC” study) (see: ClinicalTrials.gov NCT05927142\n(https://www.globenewswire.com/Tracker?data=T1F0cJVnaozkTrLvb5BtH-NnFUkH3Sc4YPCA-kfP6i2AWaLA4cSa-vC1JpzdUOEUQqUqzW5IY-oghLIF-bI_vit4wVG16qsEnR3ZNi9gILcLEWSIKPJRHbDucvKdnYXMH-Ouwr1c-tKOtl8MfuNw4VlaGYhP-ZvI25bKmxHc8qT-XfukgJ9gOme2uJq5HDswED6VDGhh-C9yE83ABla_CqAAsJoviQ4pDyxyHrX1Tu00cGS2decboOnghCrF7w-TI60qeGhZnK0psD6AVoRGt2FZOktdFCofAU8e4tLGebS6dRLaW91htBv8-wEsoe4WsHgXxwqpJ4upTHx_RTfL8A==)).\n\nThe ahead-of-schedule enrollment milestone reinforces AIM’s emphasis on\naccelerating momentum and keeps the Company on track for a planned December\n2026 evaluation of the study's primary endpoint, Clinical Benefit Rate\n(\"CBR\"), a key measure of treatment effectiveness in one of the deadliest and\nmost difficult-to-treat cancers.\n\nAIM previously reported positive year-end interim results\n(https://www.globenewswire.com/Tracker?data=tcPKxh_qs7J3h3QYmuj6QQhkz2KK9xnWilW55snBdKCyEHzg6gW5cwUCOHT4kv3KfN_mjOFWGgyHtw19SkgMgaxqT6T7ShfcY0v-GpGqZnQ8R8S7acTV6rxOxNTVD2NHnCLdasfGhb--4BEh1GvNyQ==)\nin DURIPANC and intends to publish its next interim report in the next two to\nthree weeks.\n\n\"This achievement represents another important execution milestone for the\nDURIPANC program and further strengthens the momentum behind Ampligen in\npancreatic cancer,\" said AIM Chief Executive Officer Thomas K. Equels. \"We\ncontinue to observe encouraging survival outcomes, consistently high\nquality-of-life measures and Ampligen's strong safety profile. Together with\nour ongoing Phase 3 planning efforts, orphan drug designations in the United\nStates and Europe, expanding global intellectual property portfolio, and\ngrowing body of positive clinical data, we believe Ampligen is advancing\ntoward a significant value-inflection period for AIM and, most importantly,\ntoward addressing a critical unmet need for pancreatic cancer patients.\"\n\nMr. Equels continued, \"We remain on track to complete Ampligen dosing for all\nsubjects in August, which should allow us to evaluate the study's critical\nprimary endpoint of Clinical Benefit Rate in December 2026. Clinical Benefit\nRate is defined as stable disease, partial response, or complete response six\nmonths after initiation of combination therapy.\"\n\nThe enrollment milestone further advances AIM's broader pancreatic cancer\nstrategy, which includes ongoing Phase 3 clinical trial planning and continued\nexpansion of its global regulatory and intellectual property position. The\nplanned Phase 3 program is supported by positive published data from a Dutch\ngovernment-approved Named Patient Program involving Ampligen-treated\npancreatic cancer patients, as well as encouraging findings from the ongoing\nDURIPANC study. Collectively, these programs have generated clinical\nexperience in more than 100 pancreatic cancer patients treated with Ampligen\nand continue to support the Company's strategy of advancing Ampligen toward\npivotal-stage development.\n\nDURIPANC is an investigator-initiated, exploratory, open-label, single-center\nstudy conducted through a collaboration among AIM ImmunoTech, AstraZeneca, and\nErasmus Medical Center in the Netherlands. The primary objective of the study\nis to evaluate the CBR of the combination therapy. Secondary and exploratory\nobjectives include assessing overall survival and progression-free survival,\nevaluating immune-monitoring through tissue biopsies and peripheral immune\nprofiling, and measuring patient quality of life.\n\nPancreatic cancer remains one of the most lethal malignancies worldwide and is\nprojected to become the second leading cause of cancer-related deaths in the\nUnited States. Despite decades of research, treatment options remain limited,\nhighlighting the urgent need for innovative therapeutic approaches that can\nimprove survival and quality of life for patients.\n\nAbout AIM ImmunoTech Inc.\n\nAIM ImmunoTech Inc. is an immuno-pharma company focused on the research and\ndevelopment of its lead product, Ampligen® (rintatolimod), for the treatment\nof late-stage pancreatic cancer, a lethal and unmet global health problem.\nAmpligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that\nhas shown broad-spectrum activity in clinical trials.\n\nFor more information, please visit aimimmuno.com\n(https://www.globenewswire.com/Tracker?data=ksEP8P-cxrugd3dPibbAxf3-Bc5PH7vam2rnRIEtyLtk02yzng8ZJuCUKYRaopsXH1ggriRSN3ckE-lM2zJdHg==) and\nconnect with the Company on X\n(https://www.globenewswire.com/Tracker?data=hli0cmP1t0HxeTy1xVrTnFL0dUAaYCk9i5qRTm1yodRpZa5nNPVg8hCdl2Zfz5FHTp7mNpokuzLLUUf2-DPZUw==), LinkedIn\n(https://www.globenewswire.com/Tracker?data=kDilEfwf-X0FrjI7oYeDfEgSbrM2_o66seIFuufshZ5YCHqp3jQgzfSmArlCCcxk5q1G1i4WNc_Eyc3fT7Y1QbPuoCl4Y7CGmNik490RmjUDfNH1QDwZk77ffFibCsla),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=4n1y-e0kcpy8K45DRQWUnQMbhozj710M5haS0Sp3ds2SkWNikIg3Yh6VoQNnWewAbtBthNbuyuByZKpVIfY2Bh83PS_wXdy_vqEK86AkbYw=).\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, which are intended to be covered\nby the safe harbor created by those sections. Because such statements are\nsubject to risks and uncertainties, actual results may differ materially from\nthose expressed or implied by such forward-looking statements. For all\nforward-looking statements, the Company claims the protection of the safe\nharbor for forward-looking statements contained in the Private Securities\nLitigation Reform Act of 1995. Forward-looking statements may be identified by\nthe use of words such as “believes,” “expects,” “intends,”\n“may,” “will,” “plans,” “potential,” “anticipates,”\n“projects,” or the negative or plural of these words, or other similar\nexpressions that are predictions or indicate future events or prospects, but\nthe absence of these words does not mean that a statement is not\nforward-looking. Any forward-looking statements set forth in this press\nrelease speak only as of the date hereof. These forward-looking statements are\nbased upon the Company’s current expectations, estimates, assumptions, and\nbeliefs concerning future events and conditions, which are subject to change.\nSuch forward-looking statements may include statements relating to: the timing\nof evaluation of the DURIPANC study's primary endpoint; the Clinical Benefit\nRate; the anticipated survival outcomes, quality-of-life measures, and the\nsafety profile of subjects and the expected timing thereof; the Company’s\nPhase 3 clinical trial planning efforts; the potential advancement of Ampligen\ntoward pivotal-stage development; the timing of commencement, enrollment,\ncompletion, and results of clinical trials; IP expansion and regulatory\nprogress; and timing for receiving government approvals, if at all. The\nCompany does not undertake to update any of these forward-looking statements\nto reflect events or circumstances that occur after the date hereof, except as\nrequired by applicable law. The Company is in various stages of seeking to\ndetermine whether Ampligen will be effective in the treatment of multiple\ntypes of viral diseases, cancers, and immune-deficiency disorders, and\ndisclosures in the Company’s reports filed with the U.S. Securities and\nExchange Commission (the “SEC”), on its website, and in its press releases\nset forth its current and anticipated future activities. These activities are\nsubject to change for a number of reasons. Significant additional testing and\ntrials will be required to determine whether Ampligen(®) will be effective\nin the treatment of these conditions. Results obtained in preclinical studies\ndo not necessarily predict results in humans. Human clinical trials will be\nnecessary to prove whether or not Ampligen(®) will be efficacious in humans.\nNo assurance can be given as to whether current or planned clinical trials\nwill be successful or yield favorable data, and the trials are subject to many\nfactors including lack of regulatory approval(s), lack of study drug, lack of\nadequate funding, or a change in priorities at the institutions sponsoring\nother trials. Even if these clinical trials are initiated, the Company cannot\nassure that the clinical studies will be successful or yield any useful data.\nNo assurance can be given that the findings in preliminary studies will prove\ntrue or that such studies will yield favorable results, or that future studies\nwill not result in findings that are different from those reported in the\nstudies referenced in the Company’s reports filed with the SEC, on the\nCompany’s website, and in its press releases. Operating in foreign countries\ncarries with it a number of risks, including potential difficulties in\nenforcing intellectual property rights. The Company cannot assure that its\npotential foreign operations will not be adversely affected by these risks.\n\nFor a detailed discussion of risk factors that could cause actual results to\ndiffer materially from those described in the forward-looking statements,\nplease review the “Risk Factors” section in the Company’s most recent\nAnnual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and\nCurrent Reports on Form 8-K filed with the SEC. The forward-looking statements\nin this press release should be read in conjunction with such filings. These\nfilings are available at www.sec.gov and www.aimimmuno.com. The information\nfound on the Company’s website is not incorporated by reference into this\npress release and is included for reference purposes only.\n\nInvestor Contact:\n\nJTC Team, LLC\nJenene Thomas\n908.824.0775\nAIM@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8e85b83b-047f-4f99-9c51-1aa232ffe9bb)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX75c4bp","title":"AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones","author":"Globe Newswire","ticker":"AIM","created":"2026-06-01T12:58:00.099Z","tickers":["AIM"],"exchange":"NYSE American","article_body":"OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.\n(https://www.globenewswire.com/Tracker?data=5rGktpu2xpylAlM1y0tFodD_VXgDBHDlHw4FDZcDFbqKa6hNgjNvdAuwkwQqG9W282fLruEWsBhNPOgubgXh1X_AFGJ1jtUnCxm5k0O2WAI=)\n(NYSE American: AIM) (“AIM” or the “Company”) today announced a\nsignificant milestone in its pancreatic cancer development program, with\nenrollment of the final subject, barring disqualifying pre-treatment\ncircumstances. The final planned subject is scheduled for treatment in\nmid-June, surpassing the Company's original enrollment target of July 2026 in\nthe Phase 2 clinical trial of AIM’s drug Ampligen(®) (rintatolimod)\ncombined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor\nImfinzi(®) (durvalumab) in the treatment of metastatic pancreatic cancer\npatients with stable disease post-FOLFIRINOX standard of care (the\n“DURIPANC” study) (see: ClinicalTrials.gov NCT05927142\n(https://www.globenewswire.com/Tracker?data=T1F0cJVnaozkTrLvb5BtH-NnFUkH3Sc4YPCA-kfP6i2AWaLA4cSa-vC1JpzdUOEUQqUqzW5IY-oghLIF-bI_vit4wVG16qsEnR3ZNi9gILcLEWSIKPJRHbDucvKdnYXMH-Ouwr1c-tKOtl8MfuNw4VlaGYhP-ZvI25bKmxHc8qT-XfukgJ9gOme2uJq5HDswED6VDGhh-C9yE83ABla_CqAAsJoviQ4pDyxyHrX1Tu00cGS2decboOnghCrF7w-TI60qeGhZnK0psD6AVoRGt2FZOktdFCofAU8e4tLGebS6dRLaW91htBv8-wEsoe4WsHgXxwqpJ4upTHx_RTfL8A==)).\n\nThe ahead-of-schedule enrollment milestone reinforces AIM’s emphasis on\naccelerating momentum and keeps the Company on track for a planned December\n2026 evaluation of the study's primary endpoint, Clinical Benefit Rate\n(\"CBR\"), a key measure of treatment effectiveness in one of the deadliest and\nmost difficult-to-treat cancers.\n\nAIM previously reported positive year-end interim results\n(https://www.globenewswire.com/Tracker?data=tcPKxh_qs7J3h3QYmuj6QQhkz2KK9xnWilW55snBdKCyEHzg6gW5cwUCOHT4kv3KfN_mjOFWGgyHtw19SkgMgaxqT6T7ShfcY0v-GpGqZnQ8R8S7acTV6rxOxNTVD2NHnCLdasfGhb--4BEh1GvNyQ==)\nin DURIPANC and intends to publish its next interim report in the next two to\nthree weeks.\n\n\"This achievement represents another important execution milestone for the\nDURIPANC program and further strengthens the momentum behind Ampligen in\npancreatic cancer,\" said AIM Chief Executive Officer Thomas K. Equels. \"We\ncontinue to observe encouraging survival outcomes, consistently high\nquality-of-life measures and Ampligen's strong safety profile. Together with\nour ongoing Phase 3 planning efforts, orphan drug designations in the United\nStates and Europe, expanding global intellectual property portfolio, and\ngrowing body of positive clinical data, we believe Ampligen is advancing\ntoward a significant value-inflection period for AIM and, most importantly,\ntoward addressing a critical unmet need for pancreatic cancer patients.\"\n\nMr. Equels continued, \"We remain on track to complete Ampligen dosing for all\nsubjects in August, which should allow us to evaluate the study's critical\nprimary endpoint of Clinical Benefit Rate in December 2026. Clinical Benefit\nRate is defined as stable disease, partial response, or complete response six\nmonths after initiation of combination therapy.\"\n\nThe enrollment milestone further advances AIM's broader pancreatic cancer\nstrategy, which includes ongoing Phase 3 clinical trial planning and continued\nexpansion of its global regulatory and intellectual property position. The\nplanned Phase 3 program is supported by positive published data from a Dutch\ngovernment-approved Named Patient Program involving Ampligen-treated\npancreatic cancer patients, as well as encouraging findings from the ongoing\nDURIPANC study. Collectively, these programs have generated clinical\nexperience in more than 100 pancreatic cancer patients treated with Ampligen\nand continue to support the Company's strategy of advancing Ampligen toward\npivotal-stage development.\n\nDURIPANC is an investigator-initiated, exploratory, open-label, single-center\nstudy conducted through a collaboration among AIM ImmunoTech, AstraZeneca, and\nErasmus Medical Center in the Netherlands. The primary objective of the study\nis to evaluate the CBR of the combination therapy. Secondary and exploratory\nobjectives include assessing overall survival and progression-free survival,\nevaluating immune-monitoring through tissue biopsies and peripheral immune\nprofiling, and measuring patient quality of life.\n\nPancreatic cancer remains one of the most lethal malignancies worldwide and is\nprojected to become the second leading cause of cancer-related deaths in the\nUnited States. Despite decades of research, treatment options remain limited,\nhighlighting the urgent need for innovative therapeutic approaches that can\nimprove survival and quality of life for patients.\n\nAbout AIM ImmunoTech Inc.\n\nAIM ImmunoTech Inc. is an immuno-pharma company focused on the research and\ndevelopment of its lead product, Ampligen® (rintatolimod), for the treatment\nof late-stage pancreatic cancer, a lethal and unmet global health problem.\nAmpligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that\nhas shown broad-spectrum activity in clinical trials.\n\nFor more information, please visit aimimmuno.com\n(https://www.globenewswire.com/Tracker?data=ksEP8P-cxrugd3dPibbAxf3-Bc5PH7vam2rnRIEtyLtk02yzng8ZJuCUKYRaopsXH1ggriRSN3ckE-lM2zJdHg==) and\nconnect with the Company on X\n(https://www.globenewswire.com/Tracker?data=hli0cmP1t0HxeTy1xVrTnFL0dUAaYCk9i5qRTm1yodRpZa5nNPVg8hCdl2Zfz5FHTp7mNpokuzLLUUf2-DPZUw==), LinkedIn\n(https://www.globenewswire.com/Tracker?data=kDilEfwf-X0FrjI7oYeDfEgSbrM2_o66seIFuufshZ5YCHqp3jQgzfSmArlCCcxk5q1G1i4WNc_Eyc3fT7Y1QbPuoCl4Y7CGmNik490RmjUDfNH1QDwZk77ffFibCsla),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=4n1y-e0kcpy8K45DRQWUnQMbhozj710M5haS0Sp3ds2SkWNikIg3Yh6VoQNnWewAbtBthNbuyuByZKpVIfY2Bh83PS_wXdy_vqEK86AkbYw=).\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, which are intended to be covered\nby the safe harbor created by those sections. Because such statements are\nsubject to risks and uncertainties, actual results may differ materially from\nthose expressed or implied by such forward-looking statements. For all\nforward-looking statements, the Company claims the protection of the safe\nharbor for forward-looking statements contained in the Private Securities\nLitigation Reform Act of 1995. Forward-looking statements may be identified by\nthe use of words such as “believes,” “expects,” “intends,”\n“may,” “will,” “plans,” “potential,” “anticipates,”\n“projects,” or the negative or plural of these words, or other similar\nexpressions that are predictions or indicate future events or prospects, but\nthe absence of these words does not mean that a statement is not\nforward-looking. Any forward-looking statements set forth in this press\nrelease speak only as of the date hereof. These forward-looking statements are\nbased upon the Company’s current expectations, estimates, assumptions, and\nbeliefs concerning future events and conditions, which are subject to change.\nSuch forward-looking statements may include statements relating to: the timing\nof evaluation of the DURIPANC study's primary endpoint; the Clinical Benefit\nRate; the anticipated survival outcomes, quality-of-life measures, and the\nsafety profile of subjects and the expected timing thereof; the Company’s\nPhase 3 clinical trial planning efforts; the potential advancement of Ampligen\ntoward pivotal-stage development; the timing of commencement, enrollment,\ncompletion, and results of clinical trials; IP expansion and regulatory\nprogress; and timing for receiving government approvals, if at all. The\nCompany does not undertake to update any of these forward-looking statements\nto reflect events or circumstances that occur after the date hereof, except as\nrequired by applicable law. The Company is in various stages of seeking to\ndetermine whether Ampligen will be effective in the treatment of multiple\ntypes of viral diseases, cancers, and immune-deficiency disorders, and\ndisclosures in the Company’s reports filed with the U.S. Securities and\nExchange Commission (the “SEC”), on its website, and in its press releases\nset forth its current and anticipated future activities. These activities are\nsubject to change for a number of reasons. Significant additional testing and\ntrials will be required to determine whether Ampligen(®) will be effective\nin the treatment of these conditions. Results obtained in preclinical studies\ndo not necessarily predict results in humans. Human clinical trials will be\nnecessary to prove whether or not Ampligen(®) will be efficacious in humans.\nNo assurance can be given as to whether current or planned clinical trials\nwill be successful or yield favorable data, and the trials are subject to many\nfactors including lack of regulatory approval(s), lack of study drug, lack of\nadequate funding, or a change in priorities at the institutions sponsoring\nother trials. Even if these clinical trials are initiated, the Company cannot\nassure that the clinical studies will be successful or yield any useful data.\nNo assurance can be given that the findings in preliminary studies will prove\ntrue or that such studies will yield favorable results, or that future studies\nwill not result in findings that are different from those reported in the\nstudies referenced in the Company’s reports filed with the SEC, on the\nCompany’s website, and in its press releases. Operating in foreign countries\ncarries with it a number of risks, including potential difficulties in\nenforcing intellectual property rights. The Company cannot assure that its\npotential foreign operations will not be adversely affected by these risks.\n\nFor a detailed discussion of risk factors that could cause actual results to\ndiffer materially from those described in the forward-looking statements,\nplease review the “Risk Factors” section in the Company’s most recent\nAnnual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and\nCurrent Reports on Form 8-K filed with the SEC. The forward-looking statements\nin this press release should be read in conjunction with such filings. These\nfilings are available at www.sec.gov and www.aimimmuno.com. The information\nfound on the Company’s website is not incorporated by reference into this\npress release and is included for reference purposes only.\n\nInvestor Contact:\n\nJTC Team, LLC\nJenene Thomas\n908.824.0775\nAIM@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8e85b83b-047f-4f99-9c51-1aa232ffe9bb)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-01T12:58:00.146343247Z","server_sent_at_ms":1780318680146},"received_at":"2026-06-01T12:58:00.292Z","source_url":null},"analysis":{"id":"40237","press_release_id":"50806","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"AIM ImmunoTech completed enrollment in its Phase 2 DURIPANC study ahead of schedule, with the final subject scheduled for treatment in mid-June 2026.\n\nThe study evaluates Ampligen (rintatolimod) combined with AstraZeneca’s Imfinzi (durvalumab) in metastatic pancreatic cancer patients.\n\nThe company remains on track to evaluate the primary endpoint, Clinical Benefit Rate, in December 2026, following planned dosing completion in August.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"AIM hits Phase 2 enrollment milestone early; watch for interim data in weeks and primary readout in Dec 2026."},"keyFigures":{"drugName":"Ampligen (rintatolimod)","phaseOfTrial":"Phase 2","customDimensions":{"study_name":"DURIPANC","enrollment_target_date":"July 2026","actual_enrollment_completion":"mid-June 2026","primary_endpoint_evaluation_date":"December 2026","total_patients_treated_in_program":"more than 100"}},"quotedText":"This achievement represents another important execution milestone for the DURIPANC program and further strengthens the momentum behind Ampligen in pancreatic cancer","namedEntities":{"people":[{"name":"Thomas K. Equels","role":"Chief Executive Officer"}],"products":["Ampligen","rintatolimod","Imfinzi","durvalumab"],"companies":[{"name":"AIM ImmunoTech Inc.","ticker":"AIM"},{"name":"AstraZeneca","relationship":"partner"},{"name":"Erasmus Medical Center","relationship":"partner"},{"name":"JTC Team, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Ahead-of-schedule enrollment completion in a Phase 2 trial is a positive execution milestone, but it is not a binary regulatory event or a final readout. The primary endpoint evaluation is still 6 months away (Dec 2026)."},"tickerRelevance":{"others":[{"ticker":"AZN","relevance":"partner"}],"primary":"AIM"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"clinical_milestone","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"AIM ImmunoTech completed enrollment in its Phase 2 DURIPANC study ahead of schedule, with the final subject scheduled for treatment in mid-June 2026.\n\nThe study evaluates Ampligen (rintatolimod) combined with AstraZeneca’s Imfinzi (durvalumab) in metastatic pancreatic cancer patients.\n\nThe company remains on track to evaluate the primary endpoint, Clinical Benefit Rate, in December 2026, following planned dosing completion in August.","key_figures":{"drugName":"Ampligen (rintatolimod)","phaseOfTrial":"Phase 2","customDimensions":{"study_name":"DURIPANC","enrollment_target_date":"July 2026","actual_enrollment_completion":"mid-June 2026","primary_endpoint_evaluation_date":"December 2026","total_patients_treated_in_program":"more than 100"}},"named_entities":{"people":[{"name":"Thomas K. Equels","role":"Chief Executive Officer"}],"products":["Ampligen","rintatolimod","Imfinzi","durvalumab"],"companies":[{"name":"AIM ImmunoTech Inc.","ticker":"AIM"},{"name":"AstraZeneca","relationship":"partner"},{"name":"Erasmus Medical Center","relationship":"partner"},{"name":"JTC Team, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-01T12:59:20.109Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"clinical_milestone","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"durationMs":79797,"modelName":"george-droid-qwen-72b"}}